This prospective study aimed to characterize the population pharmacokinetics of intravenous oxycodone and to determine the minimum effective concentration (MEC) and minimum effective analgesic concentration (MEAC) of oxycodone for major open intra-abdominal surgery.
Introduction
Recently, use of the opioid oxycodone has increased markedly. Indeed, in several countries, it has replaced morphine as a rescue analgesic [3] . There are formulations for immediate and extended oral release, oral syrup and intravenous use. In 2013, intravenous oxycodone was approved for market by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for moderate to severe pain, including postoperative intravenous patient-controlled analgesia (IV PCA) [4] . Currently, the most common opioid analgesic used for IV PCA in Korea is fentanyl, and the clinical experience with IV PCA with oxycodone in Korea has been extremely limited. The dosage regimen for postoperative pain relief with intravenous oxycodone that was approved by the MFDS is an IV loading bolus of 2 mg, followed by IV PCA consisting of demand boluses of 1 mg and no background infusion [4] . However, this dosing strategy might not be suitable for all patients because several studies have shown that oxycodone pharmacokinetics vary markedly [5] [6] [7] . Age is a particularly significant covariate for metabolic oxycodone clearance [5, 6] . Hence, older patients might require lower and more carefully titrated doses to avoid harmful adverse events. Two studies have characterized the population pharmacokinetics of intravenous oxycodone, but both had some limitations [6, 8] . One study was performed in children, while the other, by Saari et al., had a delayed initial sampling time and a relatively large number of healthy young volunteers, and calculated lean body mass (LBM) using the James formula [6, 8] . Hence, it is necessary to perform a new population pharmacokinetic study to determine the inter-individual variability in pharmacokinetic parameters in surgical patients who require IV PCA.
Earlier studies showed that laparoscopic cholecystectomy and cardiac surgery differ in terms of the minimum effective concentration (MEC) and minimum effective analgesic concentration (MEAC) by at least 20 ng ml À1 [9, 10] . Thus, laparoscopic cholecystectomy requires a smaller IV oxycodone dose to treat pain effectively and to induce analgesia than cardiac surgery. This surgical procedure-related variability suggests that the dosage regimen of IV PCA with oxycodone might have to be adjusted for major intra-abdominal surgeries, such as stomach, colorectal and hepatobiliary surgeries, which are the most common surgeries in Korea. To the best of our knowledge, the MEC and MEAC with oxycodone for major intra-abdominal surgeries have not been evaluated. The aims of this study were to characterize the population pharmacokinetics of IV oxycodone following a single IV bolus of 0.1 mg kg À1 in surgical patients and to determine the MEC and MEAC of intravenous oxycodone for major intra-abdominal open surgeries such as stomach, colorectal and hepatobiliary surgeries.
Materials and Methods

Patient population
This study consisted of two clinical trials. Both clinical trials were approved by the IRB (Institutional Review Board) of AMC (Asan Medical Centre) (2014-0600 for the pharmacokinetic study, 2014-0601 for the analgesic-potency study) and were registered on an international clinical trials registry platform (http://cris.nih.go.kr, KCT0001336 for the pharmacokinetic study; KCT0001340 for the analgesic-potency study). Written informed consent was obtained from all of the patients. The patient groups in both clinical trials consisted of all consecutive patients who were scheduled to undergo elective stomach, colorectal or hepatobiliary surgery between August 2014 and March 2015 at AMC (a tertiary referral centre) and who had an American Society of Anesthesiologists Physical Status (ASA PS) of 1 or 2. The patients in the pharmacokinetic and analgesic-potency study were enrolled in August 2014-March 2015 and August 2014-February 2015, respectively. Patients were excluded if they were allergic to oxycodone, had long-term use of opioid medications, were pregnant, had a history of hepatic, cardiopulmonary or renal disease, and/or had a history of chronic pain. Moreover, in the analgesic-potency study, patients undergoing laparoscopic surgery were excluded.
Study procedures
All of the patients fasted for 6-8 h prior to surgery. They were monitored routinely with conventional equipment in the operating theatre. Anaesthesia was induced and maintained with target effect site concentration-controlled infusion of propofol and remifentanil (Asan Pump, version 2.1.3, Bionet Co., Ltd., Seoul, Republic of Korea) [11, 12] . Intervention for the analgesic-potency study
At least 30 min before the anticipated end of surgery, the patients were administered a 0.1 mg kg À1 intravenous bolus of oxycodone, taken to the postoperative anaesthesia care unit (PACU), and assessed for pain every 10 min using a visual analogue scale (VAS) (0 = no pain; 10 = the most severe pain). Pain was measured at rest and when the wound areas were compressed with a force of 20 N (i.e., 2 kg of pressure imposed by three fingers on a 10 cm 2 area). The wound compression was performed by nurses who were trained with an algometer (Commander Algometer, J Tech Medical Industries, Midvale, UT, USA) to apply this force consistently. On the first occasion that wound pain at rest and during compression was rated as ≥3 or ≥5, respectively, the first venous blood sample was obtained to determine the MEC of oxycodone [9] . The patient was then administered IV oxycodone 2 mg (body weight < 80 kg) or 3 mg (>80 kg) every 10 min until the VAS assessments showed that the pain intensity had decreased to <3 at rest and <5 on wound compression. At this point, the second blood sample was obtained, and the MEAC of oxycodone was measured [9] . This process for measuring MEC and MEAC was repeated again in each patient. During the study period in the PACU, heart rate, non-invasive blood pressure, respiratory rate and adverse events were monitored and recorded every 10 min. The sedation level was assessed every 30 min using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score.
Blood sample acquisition and assay
Blood samples were collected in ethylene-diamine-tetraacetic acid (EDTA) tubes and were centrifuged for 10 min at 1500 × g. The plasma was stored at À80°C until assay. The plasma concentration of oxycodone hydrochloride was determined using a method of fully validated liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). The plasma samples (0.2 ml) were mixed with 0.02 ml of an internal standard (oxycodone-d6) working solution, extracted with tert butyl methyl ether by vortexmixing for 2 min at high speed, centrifuged at 27 000 × g for 5 min, and evaporated under a stream of nitrogen at less than 45°C. The residues were dissolved in 0. 
Non-compartmental analysis of oxycodone
Plasma concentration-time data were fit by noncompartmental methods to determine the AUC last (area under the curve from administration to the last measured concentration), AUC inf (area under the curve from administration to infinity), and λz (apparent terminal rate constant) using WinNonlin software, version 6.3 (Pharsight, a Certara Company, St. Louis, MO, USA).
Population pharmacokinetic analysis
A population pharmacokinetic analysis was performed with NONMEM VII level 3 (ICON Development Solutions, Ellicott City, MD, USA). A log-normal model was used to estimate the inter-individual random variabilities (IIV) of pharmacokinetic parameters, and diagonal matrices were applied to estimate the various distributions of η, where η represented the IIV. Combined additive and constant CV residual error models were applied to the model building. NONMEM computed the minimum objective function value (OFV), a statistical equivalent to the À2 log likelihood of the model. An α level of 0.05, which corresponds to a reduction in the OFV of 3.84 (Chi-square distribution, degrees of freedom = 1, P < 0.05), was used to distinguish between hierarchical models [13] . One-, two-, and three-compartment disposition models with first-order elimination were tested. The covariates that were analysed were age, sex (0 = male, 1 = female), weight, height, body surface area [14] , body mass index, ideal body weight [15] , lean body mass [16] , systolic blood pressure, diastolic blood pressure, mean arterial pressure [17] , heart rate, hourly fluid volume infused and hourly urine output during the study period, and blood loss during operation. Non-parametric bootstrap analysis served to validate the models internally (fit4NM 3.7.9, http://www.fit4nm.org/ download, last accessed 17 October 2011) [18] . Predictive checks and random permutation tests were also performed using fit4NM 3.7.9 [19, 20] . Simulations were performed to characterize the effect of covariates on the oxycodone pharmacokinetics, using the estimated pharmacokinetic parameters of the final model.
Determination of analgesic potency using logistic regression
Every measured plasma oxycodone concentration was joined to 0 (MEC) or 1 (MEAC). The relationship between the probability of analgesia and the measured plasma oxycodone concentration was analysed using a sigmoid E max model:
where C p is the measured plasma oxycodone concentration, C p50 is the plasma concentration associated with a 50% probability of analgesia, and γ is the steepness of the concentration vs. response relation. The likelihood, L, of the observed response, R, is described by the following equation:
where Prob is the probability of analgesia. Model parameters were estimated using the option "LIKELIHOOD LAPLACE METHOD = conditional" in NONMEM. The IIV of C p50 and γ was modelled using a log-normal model.
Simulation
Deterministic simulations that considered neither the interindividual nor the intra-individual random variability were performed using Asan Pump software. The changes in oxycodone plasma concentration over time after a 0.1 mg kg
À1
bolus of oxycodone were simulated in hypothetical patients whose weight and height were 65 kg and 165 cm, respectively. The predicted oxycodone concentration in the plasma over time after an intravenous bolus of 0.1 mg kg À1 , followed by demand boluses of 1 mg every 15 min with or without background infusion of 1 mg h À1 , was also simulated.
Safety
Safety profiles were evaluated on the basis of the incidence of adverse events, vital signs and clinical laboratory test results. In the analgesic-potency study, the patients in the PACU were monitored in terms of heart rate, non-invasive blood pressure and respiratory rate, which were recorded every 10 min. The sedation level was assessed every 30 min using the MOAA/S score.
Statistics
Statistical analysis was conducted using SigmaStat software, version 3.5 for Windows (Systat Software, Inc., Chicago, IL, USA). The data are expressed as the means (SDs) for normally distributed continuous variables, medians (25-75%) for nonnormally distributed continuous variables, and counts and percentages for categorical variables. A P-value less than 0.05 was considered as statistically significant.
Results
Patient populations
A consort diagram of participants in the two sub-studies and the characteristics of the two patient populations are shown in Figure 1 and Table 1 , respectively.
Non-compartmental analysis
In total, 849 plasma concentration measurements from 54 patients were used to characterize the pharmacokinetics of oxycodone in patients undergoing major intra-abdominal open surgery. The plasma concentration-time data are shown in Figure 2A . The mean (SD) AUC last and AUC inf were 11.6 (3.1) and 12.1 (3.3) min μg ml À1 , respectively. The mean (SD) λz was 0.16 (0.04) h À1 . In all of the subjects, at least 80% of the total area under the curve was covered by the measured concentrations (3.7% of AUC %Extra , percentage of the extrapolated area under the curve to the total area under the curve).
Population pharmacokinetics
A three-compartment mammillary model best described the pharmacokinetics of oxycodone in surgical patients. LBM was a significant covariate for the central volume of distribution (V d ) (equation (3)), and it resulted in improvement in the OFV (20.74, P < 0.001, df = 1), compared with the basic model (number of model parameters = 14). The δ value between the basic and covariate (LBM on V 1 ) models in the randomization test was 3.70.
LBM was also a significant covariate for the slow peripheral V d (equation (4)) and led to a further improvement in OFV (36.81, P < 0.001, df = 1) compared with the OFV of a pharmacokinetic model that included LBM as a covariate for the central V d only (number of model parameters = 15). The δ value between the previous covariate (LBM on V 1 ) and present covariate (LBM on V 1 and V 3 ) pharmacokinetic models was 2.45.
Age was a significant covariate for the metabolic clearance of oxycodone (equation (5)) and resulted in an improvement in OFV (4.69, P < 0.05, df = 1) compared with the OFV of a pharmacokinetic mode that included LBM as a covariate for the central and slow peripheral V d s (number of model parameters = 16). The δ value between the previous covariate (LBM on V 1 and V 3 ) and present covariate (LBM on V 1 and V 3 , and age on Cl) pharmacokinetic models was 2.30.
LBM was also a significant covariate for the rapid peripheral V d (equation (6) ) and led to further improvement in OFV (16.81, P < 0.001, df = 1), compared with the OFV of a pharmacokinetic model that included LBM as a covariate for the central and slow peripheral volumes of distributions and age as a covariate for metabolic clearance (number of model parameters = 17). The δ value between the covariate (LBM on V 1 and V 3 , and age on Cl) and final pharmacokinetic (LBM on V 1 , V 2 and V 3 , and age on Cl) models was 1.91
Parameter estimates of the competing base and covariate pharmacokinetic models of oxycodone are described in the supplementary materials ( Table 2 ). The results of the randomization test provided sufficient evidence to conclude that the effects of LBM on V 1 , V 2 and V 3 , and age on Cl, were statistically significant. Table 3 represents the population pharmacokinetic parameter estimates and the results of nonparametric bootstrap replicates of the final pharmacokinetic model of oxycodone. Predictive checks of the final pharmacokinetic model are presented in Figure 2B . In total, 2.3% of the data were distributed outside of the 95% prediction intervals of the predictive check.
MEC, MEAC and analgesic potency
Total doses of 8 (6-12) mg and 2 (2-4) mg of oxycodone were required to achieve the first and second MEAC, respectively. A total of 200 plasma concentration measurements from 50 patients was used to determine MEC and MEAC and to perform the logistic regression analysis. At the first onset of pain (the first MEC), the median plasma concentration of oxycodone was 31.5 ng ml À1 (95% CI: 19.2-42.8 ng ml À1 ). At the first pain relief (the first MEAC), the median plasma concentration was 74.1 ng ml À1 (29.2-128.3 ng ml À1 ). The second MEC and MEAC were 63.4 (15.6-120.1) and 76.1 (32.9-132.7) ng ml À1 , respectively ( Figure 3) . The relationship between the probability of analgesia and the measured plasma oxycodone concentration is shown in Figure 4 . The C p50 (the measured plasma oxycodone concentration that was associated with a 50% probability of analgesia) estimate (SE) was 59.9 (2.40) ng ml À1 . The γ estimate (SE) and the inter-individual variability presented as %CV were 3.73 (0.729) and 182%, respectively.
Simulation
The predicted oxycodone concentration in the plasma over time after an intravenous bolus and on continuous infusion using IV PCA are shown in Figure 5 . This simulation showed that when the oxycodone loading dose was the dose approved by the MFDS (2 mg), it generated plasma oxycodone concentrations over time after surgery that were less than the MEC ( Figure 4A ). In contrast, when a 0.1 mg kg À1 bolus of oxycodone (6.5 mg for a 65 kg person) was administered as the loading dose, it generated concentrations that were higher than the MEC for 30 min after the end of surgery ( Figure 4B ). In another simulation, an intravenous Figure 1 Consort diagram of participants in the two studies. For the pharmacokinetic study, a total of 63 patients were screened, and of these, six patients were excluded due to violations of the inclusion criteria. A total of 57 patients were enrolled in this study, and seven patients dropped out from the study because of withdrawal of consent before administration of oxycodone (n = 1) and protocol deviations (n = 2). Hence, 54 patients were included in the safety and pharmacokinetic analyses. For the analgesic potency study, 61 patients were screened, and of these, four patients were excluded due to violations of the inclusion criteria. A total of 57 patients were enrolled in this study, and five patients dropped out from the study because of conversion to laparoscopic surgery (n = 3), no complaint of pain at PACU (n = 1), and withdrawal of consent at PACU (n = 1). Additionally, two patients were excluded from the evaluation of MEC, MEAC and analgesic potency of oxycodone because of protocol deviations. Hence, 52 and 50 patients were included in the safety and the MEAC analyses, respectively. PACU: post-anaesthesia care unit oxycodone loading dose of 0.1 mg kg À1 was administered at the end of surgery, and intravenous PCA with or without 1 mg h À1 background infusion was started 5 min later.
During the immediate postoperative period, the MEAC was most rapidly attained when both the higher loading dose (0.1 mg ml À1 ) and background infusion were used ( Figure 4C and 4D ).
Safety analysis
In the pharmacokinetic study, there were six adverse events in five patients during the study period. All were mild (n = 4) or moderate (n = 2) and were not caused by oxycodone. All of the adverse events resolved completely without sequelae. In one patient, the adverse event was generalized oedema that occurred after intravenous administration of 10 mg metoclopramide; it resolved after intravenous administration of 4 mg chlorpheniramine maleate. In two other patients, the adverse events were transient hyperthermia (38.5°C) and hypertension (175/93 mm Hg), which occurred on postoperative days 1 and 2, respectively; both events resolved spontaneously. In the fourth patient, the adverse event was nausea and vomiting, which occurred after administration of intravenous prophylactic antibiotics; the event resolved spontaneously after the patient emerged from anaesthesia. In the fifth patient, the adverse event was an increase in plasma creatinine level from 1.23 to 4.19 mg dl À1 ; this event arose after a magnetic resonance imaging scan.
In the analgesic-potency study, the median (25-75%) systolic blood pressure, heart rate, respiration rate and MOAA/S in the PACU were 141 (130-156) mm Hg, 80 (71-89) beats/min, 16 (13) (14) (15) (16) (17) (18) (19) breaths min À1 , and 5 (5-5), respectively. Three adverse events in three patients were reported during the study period. All were mild and resolved completely without sequelae. One event was definitely caused by oxycodone, the second was possibly caused by oxycodone, and the third was not caused by oxycodone. In one patient, the adverse event was chest tightness, which occurred 50 min after the last administration of intravenous oxycodone; the symptom resolved after intravenous administration of naloxone 60 μg. In the second patient, the adverse event was transient hypotension (68/55 mm Hg) in the PACU; it resolved after fluid administration and a change in position from supine to the Trendelenburg position. The Table 2 Parameter estimates (RSE, % CV) of competing basic and covariate pharmacokinetic models of oxycodone 
2539.4
Number of parameters (p) Predicted probability for analgesia plotted against plasma concentrations of oxycodone in the analgesic potency study. X: plasma concentration of oxycodone at MEC (minimum effective concentration); O: plasma concentration of oxycodone at MEAC (minimum effective analgesic concentration). Red solid line indicates population prediction, and black dotted lines indicate individual prediction. The estimate of measured plasma oxycodone concentration associated with a 50% probability of analgesia (C p50 ) was 59.9 ng ml A log-normal distribution of inter-individual random variability was assumed. Residual random variability was modelled using an additive (σ 1 ) plus proportional (σ 2 ) error model. Non-parametric bootstrap analysis was repeated 2000 times. RSE, relative standard error = SE/mean × 100 (%). LBM, lean body mass calculated using the Janmahasatian formula [24] .
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Discussion
In the present study, the pharmacokinetics of oxycodone were best described using a three-compartment mammillary model. This finding differed from the population pharmacokinetic study of Saari et al., who found that a twocompartment model described well the plasma concentrations of oxycodone [6] . This disparity could be explained by differences in the initial sampling time. In the study by Saari et al., the data were pooled from four studies [6] . In nearly half (47%) of the individuals in their study, the first blood sample was drawn only 15 min after the administration of intravenous oxycodone 0.1 mg kg À1 , which resulted in relatively low maximal plasma concentrations of oxycodone (approximately 100 ng ml À1 ) [6] . In contrast, in our study, blood was obtained 2.5, 5, 10, and 15 min after the intravenous administration of a 0.1 mg kg À1 bolus of oxycodone. If the first blood sample is not obtained rapidly, it is not possible to identify the rapid distribution phase, during which there is an initial striking decline in oxycodone concentration. This fact explains why a two-compartment model described well the concentration-time data of Saari et al.
There was also another drawback in the oxycodone pharmacokinetic study of Saari et al. [6] . They calculated LBM using the James equation [21] . The James equation can yield incorrect results: when LBM calculated using the James equation is plotted against body weight, an inverted parabolic function is created. In other words, when LBM is measured using the James equation, the values start to decrease as the actual body weight increases beyond a certain body weight [22, 23] . Thus, the LBM of obese patients will be underestimated. Janmahasatian et al. developed new equations that yielded adjusted fat-free mass (which is almost equivalent to LBM) for a broad range of body weights (41-216 kg) and BMIs (17-70 kg/m 2 ) [24] . In the present study, LBM, determined using the Janmahasatian formula, was used to build the covariate models. We showed that as LBM increased, the volume of distribution increased. This finding was consistent with the observations of Saari et al. [6] , who found that LBM was a significant covariate in the central volume of distribution. We also showed that the elimination of oxycodone decreased with advancing age. A previous oxycodone pharmacokinetic study with non-compartmental methods also observed that there was an age-dependent decrease in the metabolic clearance of oxycodone [5] . The present study showed that the oxycodone MEAC was reached more rapidly when a higher loading dose was used together with IV PCA with background infusion [25] . However, even with this dosage regimen, rescue analgesics might be required to relieve pain for at least 2 h after the end of surgery. The time to 90% steady state concentration was shorter with the higher loading dose of oxycodone (0.1 mg kg À1 , 6.5 mg) compared to when the loading dose was 2 mg; it was not affected by background infusion of 1 ml/h. The IV PCA regimen with background infusion achieved a higher steady state concentration regardless of the loading dose. Because LBM and age were significant covariates for the metabolic clearance of oxycodone (see Table 2 ), steady state 76.1 ng ml À1 ), and the MEAC value was higher than the corresponding MEC value in each of the patients. These findings were in accordance with the findings of a previous study [9] . These patterns could reflect the different levels of alertness at the first and second MECs and MEACs. The samples used to obtain the first and second MEC values were obtained 7.7 (4.9-12.7) and 64.8 (53.4-90.7) min after arriving in the PACU, respectively, while the samples used to determine the first and second MEAC values were obtained 54.5 ± 21.8 and 88.0 ± 28.0 min after arriving in the PACU, respectively. In general, the patients were more alert at the time that they were discharged from the PACU than at the time of arrival. Thus, patients might feel pain more severely at the point of the second MEC than at the point of the first MEC, which would explain why the second MEC was higher than the first MEC. In contrast, the patients were likely to be fully awake at both the first and second MEACs, which explains why the first and second MEACs were similar. Notably, our MEC and MEAC values were higher than those reported previously for patients after cardiac surgery (6-12 and 15-25 ng ml À1 , respectively) [10] and for patients after laparoscopic cholecystectomy (11-57 and 14-91 ng ml À1 , respectively) [9] . Both the type of surgery and perioperative care likely were largely responsible for these differences. The MEC and MEAC for the cardiac patients might have been lower than our values because these patients were infused with fentanyl at a rate of 0.1 μg kg À1 min À1 for approximately 275-285 min; the fentanyl infusion was only discontinued at the end of the operation. Moreover, for sedation, propofol infusion of 4 mg kg À1 h À1 was started after the patients arrived in the intensive care unit (ICU). In addition, the patients received 1 g paracetamol during the first 2 h in the ICU, followed by the same dose at 8-h intervals. Furthermore, pain intensity was only assessed after extubation. The long infusion of fentanyl in particular could have lowered the MEC and MEAC of oxycodone because fentanyl has a prolonged context-sensitive half-life. In contrast, the MEC and MEAC for the patients who underwent laparoscopic cholecystectomy were lower than our MEC and MEAC values likely because laparoscopic cholecystectomy results in less pain than open abdominal surgery [26] . There was a recent study to evaluate the MEC and MEAC of oxycodone in Finnish patients undergoing laparoscopic cholecystectomy [27] . The median MEC and MEAC values in patients receiving an intravenous 10 mg dose of dexketoprofen 15 min before the end of surgery were higher than those of our study. This discrepancy might be due to the enrolment of different ethnic groups. Stamer et al. reported that the CYP2D6 genotype had an impact on oxycodone metabolism in postoperative patients [28] . There are pronounced interethnic differences in the CYP2D6 allele distribution. Distributions of CYP2D6 phenotype classes predicted from genotypes between European subjects and East Asian subjects showed differences [3] . The frequency of occurrence of the poor metabolizer phenotype was higher in Europeans [3] .
Because pain is a complex sensation, the nociceptive stimulus and pain assessment scale should be standardized in analgesic studies [9, 29] . In this study, a VAS was used to assess pain at rest and with wound compression. The noxious stimulus was compression of the wound site with a standard 20 N force over a 10 cm 2 area. A previous study showed that wound compression with a standard pressure was a more feasible method for evaluating postoperative pain in the PACU than all other methods except for asking the patient to roll over in the bed [30] . There are several issues to be considered as limitations of this study. First, this population pharmacokinetic study was conducted in surgical patients experiencing pain. To exclude various factors affecting blood concentrations of opioids, including surgical stress, anaesthetics, fluid volume and blood loss, it would be appropriate to conduct pharmacokinetic studies of opioids in healthy volunteers. However, intravenous bolus administration of opioid can cause muscle rigidity. It is well known that the incidence of opioid-induced rigidity is related to the dose and the rate of administration [31] . In a clinical situation, a 0.1 mg kg À1 intravenous bolus of oxycodone is not used to relieve postoperative pain because it is likely to induce respiratory depression and muscle rigidity. In general, surgical patients receive a 2-5 mg intravenous bolus of oxycodone at a time. When muscle rigidity occurs, the volunteer could be awake and unable to move or breathe spontaneously, which might be an unethical practice. Patients who receive muscle relaxants do not experience muscle rigidity under general anaesthesia. Additionally, as mentioned above, intravenous oxycodone was approved for market by the Ministry of Food and Drug Safety of the Republic of Korea for moderate to severe pain, including postoperative intravenous patient-controlled analgesia. The results from these studies could be used to determine a suitable dosing strategy for postoperative pain management using patient-controlled analgesia with oxycodone. Hence, it would be appropriate to perform pharmacokinetic studies in surgical patients who require IV PCA. In several studies, the population pharmacokinetics of opioids have been evaluated in surgical patients [6, 17, 32, 33] . Second, physiological response to surgical insult and interactions related to concomitant medications were not considered in this study of the population pharmacokinetics of oxycodone. Surgical stress induces a series of hormonal and metabolic changes [34] . However, it is very difficult to quantify the physiological response to surgical insult as a single surrogate measurement explaining inter-individual variability of pharmacokinetic parameters. Additionally, concomitant medication including propofol, remifentanil and muscle relaxants can directly and indirectly influence the pharmacokinetics of oxycodone. In fact, pharmacokinetic differences between patients and healthy volunteers were observed with propofol [35] . Because propofol is formulated in a lipid vehicle, propofol infused during surgery can influence the distribution of oxycodone. In an experimental study, the elimination clearance and rapid and slow distribution clearance of alfentanil were decreased in the presence of propofol [36] . To the best of our knowledge, there have been no studies of pharmacokinetic interactions between oxycodone and propofol in humans. Although cardiovascular effects induced by concomitant medication have been observed in experimental studies [37, 38] , these effects might not affect the metabolism of oxycodone. Because the hepatic extraction ratio of oxycodone is not high [39] , oxycodone clearance depends on hepatic enzyme capacity rather than hepatic blood flow, which might explain why blood pressure was not a significant covariate on clearance. Hepatic function, evaluated by laboratory tests and abdominal computed tomography, was normal in the patients enrolled in this study.
Third, the concentrations of oxycodone metabolites were not measured. Oxycodone is primarily metabolized via CYP3A4/3A5 and to a lesser extent via CYP2D6 [3, 40] . Drug interactions modulating CYP3A and CYP2D6 activities have major effects on oxycodone analgesic efficacy [7] . However, little is known thus far about pharmacokinetic interactions between oxycodone and its metabolites. The concentrations of oxycodone metabolites were also not considered for the pharmacokinetics of oxycodone in previous studies [6, 8] .
In conclusion, the time course of plasma oxycodone concentration was described well by the three-compartment mammillary model. LBM and age were significant covariates for the volume of distribution and metabolic clearance, respectively, in the final pharmacokinetic model of oxycodone. The MEAC and analgesic potency of oxycodone in major intra-abdominal open surgeries were approximately 75 and 60 ng ml À1 , respectively.
